Características clínico-epidemiológicas y patrones de prescripción para quemaduras en tres hospitales de Lima, Perú / Clinical-epidemiological characteristics and prescribing patterns for burns in three hospitals in Lima, Peru

RESUMEN Con el objetivo de describir las características clínico-epidemiológicas y los patrones de prescripción médica de pacientes con quemaduras de primer y segundo grado que acudieron a tres hospitales de referencia de Lima, se realizó un estudio transversal donde se recogieron datos demográficos, antecedentes médicos, evaluación clínica y tratamiento recibido en 561 participantes. El uso de antibióticos y de agentes humectantes se dio en 64,7% y 4,2% en los centros de atención inmediata; y en 41,7% y 44,7% en los servicios de atención especializada en quemaduras. La sulfadiazina argéntica fue el antibiótico tópico más utilizado en los servicios de atención inmediata, en comparación con los servicios de quemados (80,2% vs 34,5%). El manejo de quemaduras fue más exhaustivo en los servicios de quemados que en los de atención inmediata. Asimismo, más de un cuarto de los pacientes que acudieron por emergencia lo hicieron luego de 24 horas de ocurrida la quemadura.

ABSTRACT In order to describe the clinical-epidemiological characteristics and medical prescription patterns of patients with first- and second-degree burns who visited three reference hospitals in Lima, a cross-sectional study was carried out to collect data on demographics, medical history, clinical evaluation, and treatment received by 561 participants. The use of antibiotics and moisturizing agents was 64.7% and 4.2% in immediate care centers; and 41.7% and 44.7% in specialized burn-care services. Argenic sulfadiazine was the most commonly used topical antibiotic in immediate care services compared to burned units (80.2% vs. 34.5%). Burn management was more comprehensive in burn services than in immediate care. Also, more than a quarter of the patients who sought emergency care did so within 24 hours of the burn.

Economic burden of inpatients infected with Klebsiella pneumoniae carbapenemase / Impacto econômico do tratamento de pacientes infectados com Klebsiella pneumoniae carbapenemase

ABSTRACT Objective: To estimate the direct medical costs of drug therapy of Klebsiella pneumoniae carbapenemase (KPC) infection patients in hospital-based context. Methods: A cost-of-illness study conducted with a prospective cohort design with hospitalized adults infected by KPC. Data collection was performed using an instrument composed of sociodemographic data, clinical and prescription medication. Estimates of the direct costs associated to each treatment were derived from the payer's perspective, in the case of federal public hospitals from Brazil, and included only drug costs. These costs were based on the average price available at the Brazilian Price Database Health. No discount rate was used for the cost of drugs. The costs are calculate in American Dollar (US$). Results: A total of 120 inpatients participated of this study. The total drug cost of these inpatients was US$ 367,680.85. The systemic antimicrobial group was responsible for 59.5% of total costs. The direct drug cost per patients infected by KPC was conservatively estimated at nearly US$ 4,100.00, and about of 60% of costs occurred during the period of infection. Conclusion: The findings of our study indicate a thoughtful economic hazard posed by KPC that all healthcare sectors have to face. The increasing worldwide incidence of these bacteria represents a growing burden that most health systems are unable to deal with. There is an imperative need to develop protocols and new antimicrobials to treatment of KPC, aiming to rearrange resources to increase the effectiveness of healthcare services.

RESUMO Objetivo: Estimar os custos médicos diretos da terapia medicamentosa de pacientes com infecção por carbapenemase por Klebsiella pneumoniae carbapenemase (KPC) em contexto hospitalar. Métodos: Estudo de custo de doença realizado com desenho de coorte prospectiva, com adultos hospitalizados infectados por KPC. A coleta de dados foi realizada usando instrumento composto por dados sociodemográficos, medicamentos clínicos e prescritos. As estimativas dos custos diretos associados a cada tratamento foram derivadas da perspectiva dos pagadores, no caso dos hospitais públicos federais do Brasil, e incluíram apenas custos de medicamentos, os quais basearam-se no preço médio disponível na Price Database Health do Brasil. Nenhuma taxa de desconto foi utilizada para o custo dos medicamentos. Os custos foram calculados em dólares norte-americanos (US$). Resultados: Um total de 120 pacientes hospitalizados participou do estudo. O custo total da droga desses pacientes internados foi de US$ 367,680.85. O grupo antimicrobianos de uso sistêmico foi responsável por 59,5% dos custos totais. O custo direto estimado de forma conservadora, por paciente, foi de aproximadamente US$ 4,100.00, e cerca de 60% destes se deram durante o período de infecção. Conclusão: Os achados deste estudo apontam um risco econômico importante relacionado a KPC, o qual todos os setores de saúde terão que enfrentar. A incidência mundial em elevação destas bactérias representa carga crescente, e a maioria dos sistemas de saúde é incapaz de resolvê-la. Há necessidade imperativa de se desenvolverem protocolos e novos antimicrobianos para o tratamento de KPC, com o objetivo de reorganizar os recursos para aumentar a efetividade dos serviços de saúde.